Elliott joined Brandon Capital in 2020.
Prior to joining Brandon Capital, Elliott project managed the research team at Blis Technologies Ltd. Previously, Elliott was a Commercialisation Analyst for Otago Innovation Ltd and a Scientific Officer in pharmacology at the University of Otago.
After completing his PhD in 2018, Elliott chaired the Return On Science Biotech & Pharma and Otago Momentum Investment Committees, established two Government funded student-led investment committees in New Zealand, and conducted research for Upside Biotechnologies Ltd, which focused on developing a bioengineered solution for burns victims.
Elliott is a board observer of Amaroq Therapeutics, and a director of Cadmus Animal Health and TamoRx.
Elliott has a PhD in Stem Cell Biology from the University of Auckland, and a Bachelor and Masters in Immunology from the University of Otago. He is currently an active committee member of the Return on Science Biotech & Pharma and Otago Momentum Investment Committees.